CDC Warns of 'Rhino Tranq': Medetomidine-Laced Fentanyl Resists Naloxone and Triggers Severe Withdrawal

Nicknamed "rhino tranq," "mede," or "dex" on the street, medetomidine is not approved for human use. Its dextro-isomer, dexmedetomidine, is used in hospital settings for procedural sedation, but the racemic form now appearing in the drug supply is an animal tranquilizer designed for dogs. Unlike the xylazine-fentanyl combination known as "tranq," medetomidine presents a distinct clinical challenge: overdoses involving the substance often resist standard naloxone treatment, and cessation after regular use can trigger autonomic storms severe enough to require intensive care.

A 950% Surge in Law Enforcement Seizures

Medetomidine first surfaced in the illegal drug supply in 2021 and began appearing sporadically in cities like Chicago, Philadelphia, and Pittsburgh from mid-2023 through mid-2024. By late July 2024, it had been detected in drug samples and biological specimens from people using illegal opioids in at least 18 states and the District of Columbia.

The pace of proliferation has accelerated sharply. Reports submitted to the National Forensic Laboratory Information System, which captures law enforcement drug seizures nationwide, jumped from 247 medetomidine detections in 2023 to 2,616 in 2024—a 950% increase. In 2025, that figure surged another 215% to 8,233 reports. While medetomidine still comprised less than 1% of all drug reports across the U.S. in 2025, its geographic concentration is striking: 52% of reports came from the Northeast, 31% from the Midwest, 17% from the South, and fewer than 1% from the West.

Wastewater surveillance and drug product testing paint a similar picture. From October 2025 through January 2026, medetomidine was detected every week in at least one of 14 states participating in a CDC wastewater testing program. Data from CDC's Overdose Data to Action initiative and the National Institute of Standards and Technology's RaDAR program found medetomidine in nearly 35% of opioid-positive samples tested at 10 of 20 sentinel sites between July and December 2025. Eight sites detected it in more than half of their opioid-positive samples. Among samples that tested positive for medetomidine, 98% also contained fentanyl.

Naloxone Works on Opioids, But Not on Alpha-2 Agonists

The clinical presentation of a medetomidine-involved overdose closely resembles a classic opioid overdose: altered mental status, pinpoint pupils, hypoxemia. But there's a crucial difference. Medetomidine is an alpha-2 adrenergic agonist, in the same class as clonidine and xylazine. Its effects include marked bradycardia—heart rates as low as 32 beats per minute have been documented—along with hypotension and profound, often prolonged sedation.

Naloxone can reverse the respiratory depression caused by fentanyl, restoring breathing and preventing death. But it has no effect on medetomidine. As Dr. Brian Hurley, medical director of substance abuse prevention and control with the Los Angeles County Department of Public Health, explained to ABC7, "Naloxone doesn't address medetomidine intoxication, nor does it touch medetomidine withdrawal. So, that's why people will need other supportive care."

In practice, this means a person who has overdosed on fentanyl and medetomidine may resume breathing after naloxone administration but remain deeply sedated, with dangerously slow heart rate and low blood pressure. Some patients have required atropine to counteract severe bradycardia. The frequency of respiratory support and ICU admissions for medetomidine-involved overdoses is comparable to that of opioid or stimulant overdoses without medetomidine—unless withdrawal signs are present, which complicates care even further.

Overdose Clusters and Emergency Department Surges

Medetomidine's emergence has been linked to multiple overdose clusters. In May 2024, Chicago experienced an outbreak involving 12 confirmed, 26 probable, and 140 suspected medetomidine-related overdoses. Fentanyl was detected in all medetomidine-positive samples. Most patients exhibited typical opioid overdose findings but also had significant bradycardia due to medetomidine's alpha agonist effect. At least 16 people were hospitalized, and one died.

The substance's impact extends beyond acute overdose. Stopping medetomidine after regular use can precipitate a severe withdrawal syndrome similar to clonidine withdrawal, characterized by tachycardia exceeding 100 beats per minute, severe hypertension, fluctuating alertness, tremor, chest pain, and intractable nausea and vomiting. Symptoms can begin within hours of last use and peak 18 to 36 hours later. Serious complications including non-ST elevation myocardial infarction and posterior reversible encephalopathy syndrome have been documented.

From September 2024 through January 2025, 165 patients across three Philadelphia health systems were hospitalized for fentanyl withdrawal complicated by severe autonomic dysfunction, with presentations consistent with medetomidine withdrawal. Similar cases were reported in Pittsburgh from October 2024 through March 2025, where many patients required dexmedetomidine infusions—ironically, the pharmaceutical isomer of the very substance they were withdrawing from—and ICU-level care. In Maryland, medetomidine-related overdoses from July to August 2025 were frequently accompanied by withdrawal signs and symptoms, straining emergency departments and intensive care units.

Emergency department visits for non-alcohol, non-nicotine, and non-cannabis withdrawal have risen in temporal association with medetomidine detection in local drug supplies, suggesting a sustained burden on health systems.

Regional Variation and the West Coast Lag

While the Northeast and Midwest have borne the brunt of medetomidine's spread, Western states have seen far lower prevalence. All five sentinel sites in the West detected medetomidine in opioid-positive samples, but at rates ranging from just 2% to 8%. Los Angeles County's public health department has acknowledged the substance's presence locally, though Dr. Hurley noted it is "not present here at the same degree that is present in other cities on the East Coast, like Philadelphia."

The reasons for this geographic disparity remain unclear. Differences in drug trafficking routes, supplier networks, and regional demand for specific drug formulations may all play a role. What's certain is that medetomidine's westward trajectory is underway, and public health officials are working to raise awareness before prevalence accelerates.

Harm Reduction in the Medetomidine Era

The CDC's Health Alert Network notice emphasizes that naloxone should still be administered in suspected overdoses, given that fentanyl is involved in most medetomidine cases. Reversing the opioid component can restore breathing and prevent death, even if sedation and cardiovascular effects persist.

But the presence of medetomidine underscores the limitations of relying solely on naloxone. People struggling with opioid use disorder—and the harm reduction workers, family members, and bystanders who may witness an overdose—need to understand that naloxone is a critical tool but not a complete solution when adulterants are involved. Prolonged sedation, bradycardia, and hypotension may require emergency medical intervention beyond what naloxone can provide.

Dr. Hurley's advice to the public is clear: "The safest thing is to not use drugs, but if somebody is thinking about using, never use alone, have naloxone on hand, and consider using test strips to look at what's in the drug supply." Los Angeles County provides free fentanyl testing strips through community health stations located at schools, hotels, and churches. Similar programs exist in other jurisdictions, though testing for medetomidine specifically is not yet widely available outside of forensic and public health laboratories.

A Moving Target

Unlike xylazine, which has been associated with severe skin wounds and necrotic tissue, medetomidine does not appear to cause the same dermatological complications. But its cardiovascular effects and withdrawal syndrome present challenges that are, in some ways, more acute. The need for ICU-level care during withdrawal, the risk of myocardial infarction, and the potential for encephalopathy all represent serious escalations in the complexity of caring for people who use opioids laced with this substance.

The illegal drug supply in the United States has never been static. Fentanyl displaced heroin. Xylazine became ubiquitous. Benzodiazepines and novel synthetic opioids cycle in and out of circulation. Medetomidine is the latest variable in an equation that already defies easy solutions.

Public health agencies, harm reduction organizations, and frontline clinicians are racing to keep pace. Wastewater surveillance, forensic testing, and health alert networks provide early warning signals, but translating those signals into protective action at the street level remains a formidable challenge. Education campaigns, expanded access to naloxone and testing supplies, and investment in treatment and recovery infrastructure all remain essential—but they must adapt continuously to a drug market that shifts faster than policy can follow.

For now, the message from CDC is unambiguous: medetomidine is here, it's spreading, and it changes the rules. Clinicians need to be prepared for overdoses that don't fully respond to naloxone and withdrawals that mimic medical emergencies. People who use drugs need to know that the substances they're consuming may contain powerful sedatives that amplify risk in ways that are invisible until it's too late.

As the drug supply grows more unpredictable, the margin for error grows thinner. Medetomidine is one more reminder that harm reduction isn't just about reversing overdoses—it's about building systems resilient enough to respond to threats we don't yet see coming.